Type II mixed cryoglobulinaemia due to hepatitis C virus infection: The role of new direct-acting antivirals in a kidney transplant recipient
نویسندگان
چکیده
HCV infection remains prevalent in chronic kidney disease (CKD) patients.1 The frequency of chronic HCV infection among renal transplant recipients is influenced by various factors, including blood transfusion, history of previous transplantation, type and duration of renal replacement therapy.2 Liver biopsy is essential in the evaluation of liver disease in kidney transplant recipients because clinical and biochemical findings may underestimate its severity.1 Despite HCV infection in end-stage renal disease tending to have an indolent course, HCV RNA titers usually increase and liver disease may progress after kidney transplantation as a result of immunosuppression.3,2 HCV infection in kidney transplant recipients has a negative impact on patient and graft survival compared to those not infected.4 However, kidney transplant is still the best renal replacement therapy option for these patients and represents a better chance of survival than remaining on haemodialysis.4 Received for publication: Aug 8, 2016 Accepted in revised form: Dec 26, 2016
منابع مشابه
الگوهای جدید درمانی برای عفونت ویروس هپاتیت C
Hepatitis C virus (HCV) infection has affected approximately 180 million people across the world. In most cases, HCV-infection remains chronic, which expose patients at high risk of cirrhosis and hepatocellular carcinoma. The rates of disease incidence and mortality diminish as a result of successful treatment of HCV infection. Until the recent years, despite the associated toxicities and l...
متن کاملFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
Hepatitis C virus (HCV) infection has been a global health problem for decades, due to the high number of infected people and to the lack of effective and well-tolerated therapies. In the last 3 years, the approval of new direct acting antivirals characterized by high rates of virological clearance and excellent tolerability has dramatically improved HCV infection curability, especially for pat...
متن کاملرویکردهای توسعه واکسن های پیشگیری کننده و درمانی علیه ویروس هپاتیت C
Introdution: An estimated 3% of the world population is chronically infected with hepatitis C virus (HCV), and it is a major health problem that causes cirrhosis and hepatocellular carcinoma. Despite the new directly acting antivirals (DAAs) for curing chronic hepatitis C virus (HCV) infection, the control of the disease has remained a global challenge. Several reasons, including presence of as...
متن کاملNew treatment of hepatitis C (Direct Acting Antiviral)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy an...
متن کاملSuccessful treatment of chronic hepatitis C virus genotype 1b infection of a patient with compensated cirrhosis after renal transplantation using daclatasvir-asunaprevir combination therapy: a case report and literature review
Background: Hepatitis C virus (HCV) infection a major disorder that is not only a liver-related disease but also a cardiovascular complication in renal transplant recipient. Interferon-based therapy is a contraindication after transplantation because interferon is possibly induced to graft rejection. Only limited anecdotal evidence exists on the antiviral efficacy and tolerability of HCV direct...
متن کامل